immunogenicity and therapeutic targeting of recurrently mutated "public" neoantigens
Published 1 year ago • 784 plays • Length 53:45Download video MP4
Download video MP3
Similar videos
-
58:32
keynote - cancer immunology (carl h. june)
-
2:30
targeting public neoantigens in cancer immunotherapies
-
56:05
bioinformatics lecture series - targeting neoantigens
-
56:13
cancer vaccines: are we closer?
-
1:05:53
cancer immunotherapy beyond 2020
-
1:01:22
cancer neoantigens as targets for natural and therapeutic anti-tumor responses
-
1:01
harnessing neoantigens for individualized cancer immunotherapy
-
5:50
cytovia therapeutics: an nk revolution towards a cancer cure
-
3:25
evaluating the therapeutic potential of pik3ca-derived public neoantigens
-
10:14
neoantigen-targeted cd8 t-cell responses with pd-1 blockade therapy
-
2:20
neoantigens: promising targets for cancer therapy
-
1:11:29
harnessing neoantigens for individualized cancer immunotherapy
-
7:11
tumor immunogenicity biomarkers: the potential of immunoscore ic® (cd8/pdl1) in drug development
-
1:02:22
clinical cancer genetics: ready for prime time
-
0:36
managing adrenocortical carcinoma with immunotherapies
-
1:45
optimizing public neoantigen-targeting immunotherapies
-
2:53
immunotherapy: a revolution in cancer treatment
-
5:12
what are antigens and neoantigens?
-
23:51
efficient selection of tumor associated neoantigens in the design of personalized cancer vaccines